title: [Anticoagulation in cardiac pathologies (except atrial fibrillation)].
abstract: Anticoagulants, including heparins and antivitamins K are medicines which are largely prescribed in cardiology. Even though the outlines of the treatment have been clearly established for a few decades, new cardiological indications have recently appeared. The long-term treatment of cardiac valvular prosthesis by oral anticoagulants significantly reduces the risk of thrombo-embolic incident among people carrying a cardiac valvular prosthesis. In case of non-operated valvulopathy, treatment indication must be evaluated for each patient; in so doing, the connection benefit/risk must always be taken into account. In case of dilated cardiomyopathy, the treatment prescription must be limited to the patients with a high embolic risk. Other cardiological indications (apart from atrial fibrillation) must be carefully weighed up.
authors.affiliation: Département de Cardiologie, C.H.U. Tivoli, La Louvière, U.L.B.
authors.forename: P
authors.initials: P
authors.lastname: Lefebvre
authors.forename: A
authors.initials: A
authors.lastname: Friart
mesh_terms: D000925:Anticoagulants / Q000627:therapeutic use*; D001145:Arrhythmias, Cardiac / Q000628:therapy; D002311:Cardiomyopathy, Dilated / Q000628:therapy; D006331:Heart Diseases / Q000628:therapy*; D006349:Heart Valve Diseases / Q000628:therapy; D006350:Heart Valve Prosthesis; D006493:Heparin / Q000627:therapeutic use; D006801:Humans; D018570:Risk Assessment; D012307:Risk Factors; D013923:Thromboembolism / Q000517:prevention & control; D014812:Vitamin K / Q000037:antagonists & inhibitors
chemical_list: D000925:Anticoagulants; D014812:Vitamin K; D006493:Heparin